Kommuniké från årsstämma 2021 i LIDDS AB (publ)
17 mai 2021 10h30 HE
|
LIDDS AB
UPPSALA, SWEDEN – årsstämman i LIDDS AB (publ) hölls den 17 maj, 2021 Årsstämman fastställde i årsredovisningen intagen resultaträkning och balansräkning samt...
Report from LIDDS Annual General Meeting 2021
17 mai 2021 10h30 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS Annual General Meeting (AGM) was held on May 17, 2021. The AGM adopted the income statement and balance sheet and the consolidated income statement...
LIDDS Interim report January – March 2021
17 mai 2021 08h00 HE
|
LIDDS AB
JANUARY – MARCH 2021 Net sales amounted to MSEK 0.6 (0.0)Operating expenses amounted to MSEK -11.4 (-8.0)Profit/loss before and after tax amounted to MSEK -10.8 (-8.0)Earnings per share amounted to...
LIDDS Annual Report 2020
16 avr. 2021 09h00 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS publishes Annual Report for 2020 The Annual Report is attached to this press release and alos available on LIDDS website: https://liddspharma.com/investors/#financial-reports....
Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®
16 avr. 2021 03h00 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of...
KALLELSE TILL ÅRSSTÄMMA I LIDDS AB (publ)
13 avr. 2021 16h00 HE
|
LIDDS AB
UPPSALA, SWEDEN - Aktieägarna i LIDDS AB (publ), org.nr. 556580-2856, kallas till årsstämma i bolagets lokaler på Uppsala Business Park med besöksadress Rapsgatan 7 i Uppsala måndagen den 17 maj 2021...
Notice of Annual General Meeting of LIDDS AB (publ)
13 avr. 2021 16h00 HE
|
LIDDS AB
UPPSALA, SWEDEN – The shareholders of LIDDS AB (publ), corp. ID no. 556580-2856, are invited to the Annual General Meeting in the company's premises at Uppsala Business Park with visiting address...
International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules
08 avr. 2021 02h30 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the journal International Journal of Pharmaceutics has accepted a biomolecule study from LIDDS for publication. The investigation has been...
LIDDS CEO Interview with Finwire TV and Updated Company Presentation
31 mars 2021 05h00 HE
|
LIDDS AB
Finwire TV has done an interview in Swedish with LIDDS CEO, Monica Wallter, about her tenure as CEO of LIDDS, the recent company news and upcoming milestones. The interview is found here:...
LIDDS updates on the Clinical Program for Liproca Depot
30 mars 2021 02h30 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today an update on the clinical program for the prostate cancer drug candidate Liproca® Depot. Based on the interactions that LIDDS’ licensee for China,...